Is Aezs a good stock?
Is Aeterna Zentaris a buy?
What does Aeterna Zentaris do?
Why did Aezs go up today?
Why is OCGN stock down?
How do you buy stocks on wish?
Is Aeterna Zentaris a buy right now?
1 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Aeterna Zentaris in the last twelve months. There are currently 1...
How has Aeterna Zentaris' stock been impacted by COVID-19?
Aeterna Zentaris' stock was trading at $0.6795 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization...
When is Aeterna Zentaris' next earnings date?
Aeterna Zentaris is scheduled to release its next quarterly earnings announcement on Wednesday, March 23rd 2022. View our earnings forecast for Ae...
How were Aeterna Zentaris' earnings last quarter?
Aeterna Zentaris Inc. (NASDAQ:AEZS) released its quarterly earnings results on Thursday, November, 4th. The biopharmaceutical company reported ($0....
Who are Aeterna Zentaris' key executives?
Aeterna Zentaris' management team includes the following people: Klaus Wolfgang Paulini , President, Chief Executive Officer & Director Giuliano...
Who are some of Aeterna Zentaris' key competitors?
Some companies that are related to Aeterna Zentaris include eFFECTOR Therapeutics (EFTR) , Paratek Pharmaceuticals (PRTK) , Olema Pharmaceutical...
What other stocks do shareholders of Aeterna Zentaris own?
Based on aggregate information from My MarketBeat watchlists, some companies that other Aeterna Zentaris investors own include Zosano Pharma (ZSAN...
What is Aeterna Zentaris' stock symbol?
Aeterna Zentaris trades on the NASDAQ under the ticker symbol "AEZS."
Who are Aeterna Zentaris' major shareholders?
Aeterna Zentaris' stock is owned by a number of retail and institutional investors. Top institutional investors include Renaissance Technologies LL...
About Aeterna Zentaris
Aeterna Zentaris (NASDAQ:AEZS) Frequently Asked Questions
Æterna Zentaris, Inc. operates as a specialty biopharmaceutical company commercializing and developing therapeutics and diagnostic tests. Its product Macimorelin, is an oral growth hormone secretagogue receptor agonist indicated for the diagnosis of Adult Growth Hormone Deficiency.
Component Grades
1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Aeterna Zentaris in the last year. There are currently 1 buy rating for the stock.
AEZS POWR Grades
We have 9 different ratings for every stock to help you appreciate its future potential. You can unlock it all now.
AEZS Stock Summary
AEZS scores best on the Sentiment dimension, with a Sentiment rank ahead of 94.69% of US stocks.
AEZS Valuation Summary
Aeterna Zentaris Inc's market capitalization of $23,003,051 is ahead of just 3.36% of US-listed equities.
AEZS Growth Metrics
In comparison to the median Healthcare stock, AEZS's price/sales ratio is 223.68% higher, now standing at 12.3.
AEZS's Quality Factors
The 3 year net cashflow from operations growth rate now stands at 63.03%.
Latest AEZS News From Around the Web
The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
Company Profile
Below are the latest news stories about Aeterna Zentaris Inc that investors may wish to consider to help them evaluate AEZS as an investment opportunity.
Analyst Opinions
Aeterna Zentaris Inc., a specialty biopharmaceutical company, engages in developing and commercializing therapeutics and diagnostic tests. Its lead product is macimorelin, a peptidomimetic ghrelin receptor (GHSR-1a) agonist that stimulates the…
Research Reports
The Equity Summary Score is an accuracy-weighted sentiment derived from the ratings of independent research providers on Fidelity.com. It uses the past relative accuracy of the providers in determining the emphasis placed on any individual opinion. Learn More....
Signals & Forecast
This generated report* compiles independent, third-party information highlighting key fundamental and technical data, analyst opinions, stock price movement, earnings data, and industry comparisons. Available only to Fidelity customers.
Support, Risk & Stop-loss
The AEterna Zentaris Inc. stock holds buy signals from both short and long-term moving averages giving a positive forecast for the stock. Also, there is a general buy signal from the relation between the two signals where the short-term average is above the long-term average.
Is AEterna Zentaris Inc. stock A Buy?
AEterna Zentaris Inc. finds support from accumulated volume at $0.40 and this level may hold a buying opportunity as an upwards reaction can be expected when the support is being tested.
About AEterna Zentaris Inc
AEterna Zentaris Inc. holds several positive signals, but we still don't find these to be enough for a buy candidate. At the current level, it should be considered as a hold candidate (hold or accumulate) in this position whilst awaiting further development.
Golden Star Signal
Aeterna Zentaris Inc., a specialty biopharmaceutical company, engages in developing and commercializing novel treatments in oncology, endocrinology, and women's health.
Top Fintech Company
This unique signal uses moving averages and adds special requirements that convert the very good Golden Cross into a Golden Star. This signal is rare and, in most cases, gives substantial returns. From 10 000+ stocks usually only a few will trigger a Golden Star Signal per day!
